

Caroline Robert

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6937738/caroline-robert-publications-by-year.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

472
papers

91,634
citations

115
h-index

301
g-index

536
ext. papers

110,126
ext. citations

9.5
avg, IF

7.77
L-index

#	Paper	IF	Citations
472	Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for V600-Mutant Unresectable or Metastatic Melanoma.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2101601	2.2	10
471	First case of a melanocytic intrabulbar brain tumour treated with bevacizumab.. <i>European Journal of Cancer</i> , 2022 , 162, 206-208	7.5	1
470	Improved pyrexia-related outcomes associated with an adapted pyrexia adverse event management algorithm in patients treated with adjuvant dabrafenib plus trametinib: Primary results of COMBI-APLus.. <i>European Journal of Cancer</i> , 2022 , 163, 79-87	7.5	0
469	Tumor-associated high endothelial venules mediate lymphocyte entry into tumors and predict response to PD-1 plus CTLA-4 combination immunotherapy.. <i>Cancer Cell</i> , 2022 ,	24.3	9
468	Keratoacanthoma or cutaneous squamous cell carcinoma revealing a DNA mismatch repair default (Muir-Torre Syndrome). <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022 , 36 Suppl 1, 74-76	4.6	0
467	Multi-omics prediction in melanoma immunotherapy: A new brick in the wall.. <i>Cancer Cell</i> , 2022 , 40, 14-16	4.3	
466	Prognostic and predictive value of Tblockers in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma.. <i>European Journal of Cancer</i> , 2022 , 165, 97-112	7.5	0
465	Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial.. <i>Lancet, The</i> , 2022 ,	40	18
464	The "Great Debate" at Melanoma Bridge 2021, December 2nd-4th, 2021.. <i>Journal of Translational Medicine</i> , 2022 , 20, 200	8.5	
463	Positive Association Between Location of Melanoma, Ultraviolet Signature, Tumor Mutational Burden, and Response to Anti-PD-1 Therapy.. <i>JCO Precision Oncology</i> , 2021 , 5,	3.6	1
462	Redox activation of ATM enhances GSNOR translation to sustain mitophagy and tolerance to oxidative stress. <i>EMBO Reports</i> , 2021 , 22, e50500	6.5	11
461	Assessment of various efficacy outcomes using ERIVANCE-like criteria in patients with locally advanced basal cell carcinoma receiving sonidegib: results from a preplanned sensitivity analysis. <i>BMC Cancer</i> , 2021 , 21, 1244	4.8	0
460	Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma. <i>European Journal of Cancer</i> , 2021 , 158, 156-168	7.5	5
459	Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis.. <i>European Journal of Cancer</i> , 2021 , 162, 22-33	7.5	2
458	Tumour burden and efficacy of immune-checkpoint inhibitors. <i>Nature Reviews Clinical Oncology</i> , 2021 ,	19.4	17
457	Refractive changes during immunotherapy: Think diabetes!. <i>European Journal of Cancer</i> , 2021 , 158, 15-16	7.5	0
456	Circulating tumour DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus trametinib: a clinical validation study. <i>Lancet Oncology, The</i> , 2021 , 22, 370-380	21.7	21

455	Reply to E. Hindi. <i>Journal of Clinical Oncology</i> , 2021 , 39, 944-946	2.2	
454	Five-year overall survival (OS) in COLUMBUS: A randomized phase 3 trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients (pts) with BRAF V600-mutant melanoma.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 9507-9507	2.2	6
453	Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , 2021 , 22, 655-664	21.7	9
452	Loss of Ambra1 promotes melanoma growth and invasion. <i>Nature Communications</i> , 2021 , 12, 2550	17.4	14
451	Abscopal antitumor effect in a patient with melanoma and coronavirus disease 2019. <i>European Journal of Cancer</i> , 2021 , 149, 91-93	7.5	3
450	Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , 2021 , 22, 643-654	21.7	58
449	Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial. <i>Lancet Oncology</i> , 2021 , 22, 848-857	21.7	40
448	Role of Tumor-Infiltrating B Cells in Clinical Outcome of Patients with Melanoma Treated With Dabrafenib Plus Trametinib. <i>Clinical Cancer Research</i> , 2021 , 27, 4500-4510	12.9	4
447	Combination of targeted therapy and immune checkpoint blocker in a patient with xeroderma pigmentosum presenting an aggressive angiosarcoma and a recurrent non-resectable basal cell carcinoma. <i>European Journal of Cancer</i> , 2021 , 150, 130-132	7.5	
446	Adjuvant therapy in stage IIIA melanoma - AuthorsReply. <i>Lancet Oncology</i> , 2021 , 22, e300	21.7	0
445	Comparing RECIST 1.1 and iRECIST in advanced melanoma patients treated with pembrolizumab in a phase II clinical trial. <i>European Radiology</i> , 2021 , 31, 1853-1862	8	5
444	Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis. <i>British Journal of Cancer</i> , 2021 , 124, 574-580	8.7	9
443	Neoadjuvant Therapy for Melanoma: A U.S. Food and Drug Administration-Melanoma Research Alliance Public Workshop. <i>Clinical Cancer Research</i> , 2021 , 27, 394-401	12.9	3
442	Intratumoral Immunotherapy: From Trial Design to Clinical Practice. <i>Clinical Cancer Research</i> , 2021 , 27, 665-679	12.9	19
441	Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition 2021 , 9,		20
440	Interventional Radiology for Local Immunotherapy in Oncology. <i>Clinical Cancer Research</i> , 2021 , 27, 2698-2705		9
439	Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma. <i>European Journal of Cancer</i> , 2021 , 144, 182-191	7.5	23
438	The efficacy of immunotherapy for in-transit metastases of melanoma: an analysis of randomized controlled trials. <i>Melanoma Research</i> , 2021 , 31, 181-185	3.3	3

437	Effectiveness and safety of nivolumab in patients with advanced melanoma: A multicenter, observational study. <i>International Journal of Cancer</i> , 2021 , 148, 2789-2798	7.5	0
436	Prognostic value and therapeutic implications of nodal involvement in head and neck mucosal melanoma. <i>Head and Neck</i> , 2021 , 43, 2325-2331	4.2	1
435	Multiple immune-related toxicities in cancer patients treated with anti-programmed cell death protein 1 immunotherapies: a new surrogate marker for clinical trials?. <i>Annals of Oncology</i> , 2021 , 32, 936-937	10.3	0
434	Standard-Dose Pembrolizumab Plus Alternate-Dose Ipilimumab in Advanced Melanoma: KEYNOTE-029 Cohort 1C, a Phase 2 Randomized Study of Two Dosing Schedules. <i>Clinical Cancer Research</i> , 2021 ,	12.9	4
433	Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS). <i>European Journal of Cancer</i> , 2021 , 152, 116-128	7.5	2
432	Association of Adjuvant Immunotherapy Duration With Chronic Immune-Related Adverse Events. <i>JAMA Oncology</i> , 2021 , 7, 1573-1574	13.4	0
431	Immune checkpoint inhibitor-associated sarcoidosis: A usually benign disease that does not require immunotherapy discontinuation. <i>European Journal of Cancer</i> , 2021 , 158, 208-216	7.5	5
430	Impact of COVID-19 on healthcare organisation and cancer outcomes. <i>European Journal of Cancer</i> , 2021 , 153, 123-132	7.5	8
429	The plasticity of mRNA translation during cancer progression and therapy resistance. <i>Nature Reviews Cancer</i> , 2021 , 21, 558-577	31.3	11
428	Pyrexia in patients treated with dabrafenib plus trametinib across clinical trials in BRAF-mutant cancers. <i>European Journal of Cancer</i> , 2021 , 153, 234-241	7.5	4
427	Plasma proteomics identifies leukemia inhibitory factor (LIF) as a novel predictive biomarker of immune-checkpoint blockade resistance. <i>Annals of Oncology</i> , 2021 , 32, 1381-1390	10.3	8
426	The concepts of rechallenge and retreatment with immune checkpoint blockade in melanoma patients. <i>European Journal of Cancer</i> , 2021 , 155, 268-280	7.5	11
425	Efficacy, safety and factors associated with disease progression in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: An open label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib. <i>European Journal of Cancer</i> , 2021 , 154, 57-65	7.5	4
424	detection of the eIF4F translation initiation complex in mammalian cells and tissues. <i>STAR Protocols</i> , 2021 , 2, 100621	1.4	0
423	The Role of mRNA Translational Control in Tumor Immune Escape and Immunotherapy Resistance. <i>Cancer Research</i> , 2021 , 81, 5596-5604	10.1	1
422	Outcomes of patients with cancer and sarcoid-like granulomatosis associated with immune checkpoint inhibitors: A case-control study. <i>European Journal of Cancer</i> , 2021 , 156, 46-59	7.5	2
421	Troponin increase during immunotherapy: Not always myocarditis. <i>European Journal of Cancer</i> , 2021 , 157, 424-427	7.5	0
420	Absence of significant clinical benefit for a systematic routine creatine phosphokinase measurement in asymptomatic patients treated with anti-programmed death protein (ligand) 1 immune checkpoint inhibitor to screen cardiac or neuromuscular immune-related toxicities. <i>European Journal of Cancer</i> , 2021 , 157, 383-389	7.5	2

419	Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006. <i>European Journal of Cancer</i> , 2021 , 157, 391-402	7.5	2
418	Can radiation-recall predict long lasting response to immune checkpoint inhibitors?. <i>Radiotherapy and Oncology</i> , 2021 , 154, 125-127	5.3	4
417	LAG-3 and PD-1 blockade raises the bar for melanoma.. <i>Nature Cancer</i> , 2021 , 2, 1251-1253	15.4	0
416	Persistent Cancer Cells: The Deadly Survivors. <i>Cell</i> , 2020 , 183, 860-874	56.2	47
415	Adjuvant therapy with pegylated interferon-alfa2b vs observation in stage II B/C patients with ulcerated primary: Results of the European Organisation for Research and Treatment of Cancer 18081 randomised trial. <i>European Journal of Cancer</i> , 2020 , 133, 94-103	7.5	8
414	The EORTC-DeCOG nomogram adequately predicts outcomes of patients with sentinel node-positive melanoma without the need for completion lymph node dissection. <i>European Journal of Cancer</i> , 2020 , 134, 9-18	7.5	4
413	Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma 2020 , 8,		19
412	Immune Checkpoint Inhibitors for Cancer Therapy in the COVID-19 Era. <i>Clinical Cancer Research</i> , 2020 , 26, 4201-4205	12.9	25
411	Patient Experiences with Avelumab in Treatment-Naïve Metastatic Merkel Cell Carcinoma: Longitudinal Qualitative Interview Findings from JAVELIN Merkel 200, a Registrational Clinical Trial. <i>Patient</i> , 2020 , 13, 457-467	3.7	3
410	Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet, The</i> , 2020 , 395, 1835-1844	40	204
409	Survival of patients with advanced metastatic melanoma: The impact of MAP kinase pathway inhibition and immune checkpoint inhibition - Update 2019. <i>European Journal of Cancer</i> , 2020 , 130, 126-138	7.5	39
408	Prognostic 18F-FDG PET biomarkers in metastatic mucosal and cutaneous melanoma treated with immune checkpoint inhibitors targeting PD-1 and CTLA-4. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020 , 47, 2301-2312	8.8	31
407	The 2016-2019 ImmunoTOX assessment board report of collaborative management of immune-related adverse events, an observational clinical study. <i>European Journal of Cancer</i> , 2020 , 130, 39-50	7.5	17
406	Immunotherapy discontinuation - how, and when? Data from melanoma as a paradigm. <i>Nature Reviews Clinical Oncology</i> , 2020 , 17, 707-715	19.4	28
405	Systemic short chain fatty acids limit antitumor effect of CTLA-4 blockade in hosts with cancer. <i>Nature Communications</i> , 2020 , 11, 2168	17.4	95
404	Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report. <i>Annals of Oncology</i> , 2020 , 31, 961-964	10.3	222
403	Abstract CT012: Evaluation of atezolizumab (A), cobimetinib (C), and vemurafenib (V) in previously untreated patients with BRAFV600mutation-positive advanced melanoma: Primary results from the phase 3 IMspire150 trial 2020 ,		7
402	Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: New recurrence-free survival results from the EORTC 1325-MG/Keynote 054 double-blinded phase III trial at three-year median follow-up.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 10000-10000	2.2	15

401	Update on overall survival in COLUMBUS: A randomized phase III trial of encorafenib (ENCO) plus binimetinib (BINI) versus vemurafenib (VEM) or ENCO in patients with BRAF V600-mutant melanoma.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 10012-10012	2.2	10
400	Melanoma recurrence after adjuvant targeted therapy: A multicenter analysis.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 10016-10016	2.2	4
399	Cetuximab is efficient and safe in patients with advanced cutaneous squamous cell carcinoma: a retrospective, multicentre study. <i>Oncotarget</i> , 2020 , 11, 378-385	3.3	13
398	Management of Melanoma Brain Metastasis 2020 , 281-287		
397	Dermatological Complications of Systemic Therapies for Melanoma 2020 , 1337-1358		
396	Bariatric surgery in a patient treated with targeted therapies for metastatic melanoma: a case report. <i>Melanoma Research</i> , 2020 , 30, 629-630	3.3	
395	Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAF-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial. <i>Lancet Oncology</i> , 2020 , 21, 358-372	21.7	49
394	Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma. <i>European Journal of Cancer</i> , 2020 , 126, 33-44	7.5	74
393	Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial. <i>JAMA Oncology</i> , 2020 , 6, 519-527	13.4	148
392	Immune checkpoint inhibitors in melanoma in the metastatic, neoadjuvant, and adjuvant setting. <i>Current Opinion in Oncology</i> , 2020 , 32, 106-113	4.2	27
391	KEYNOTE-716: Phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma. <i>Future Oncology</i> , 2020 , 16, 4429-4438	3.6	23
390	Rationale for Immune Checkpoint Inhibitors Plus Targeted Therapy in Metastatic Melanoma: A Review. <i>JAMA Oncology</i> , 2020 , 6, 1957-1966	13.4	15
389	Five-Year Outcomes With Nivolumab in Patients With Wild-Type Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3937-3946	2.2	39
388	Immune Checkpoint Inhibitor Therapy Aggravates T Cell-Driven Plaque Inflammation in Atherosclerosis. <i>JACC: CardioOncology</i> , 2020 , 2, 599-610	3.8	18
387	ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee. <i>Annals of Oncology</i> , 2020 , 31, 1435-1448	10.3	49
386	Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i. <i>Nature Medicine</i> , 2020 , 26, 1557-1563	50.5	41
385	Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma: Pooled Analysis of 3 Clinical Trials. <i>JAMA Oncology</i> , 2020 , 6, 1256-1264	13.4	27
384	Melanoma Persister Cells Are Tolerant to BRAF/MEK Inhibitors via ACOX1-Mediated Fatty Acid Oxidation. <i>Cell Reports</i> , 2020 , 33, 108421	10.6	19

383	LBA43 Spartalizumab plus dabrafenib and trametinib (Sparta-DabTram) in patients (pts) with previously untreated BRAF V600E mutant unresectable or metastatic melanoma: Results from the randomized part 3 of the phase III COMBI-i trial. <i>Annals of Oncology</i> , 2020 , 31, S1172	10.3	36
382	PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma. <i>Nature Communications</i> , 2020 , 11, 6262	17.4	20
381	Intratumoural immunotherapies for unresectable and metastatic melanoma: current status and future perspectives. <i>British Journal of Cancer</i> , 2020 , 123, 885-897	8.7	15
380	Pimasertib Versus Dacarbazine in Patients With Unresectable -Mutated Cutaneous Melanoma: Phase II, Randomized, Controlled Trial with Crossover. <i>Cancers</i> , 2020 , 12,	6.6	12
379	A decade of immune-checkpoint inhibitors in cancer therapy. <i>Nature Communications</i> , 2020 , 11, 3801	17.4	289
378	ESMO consensus conference recommendations on the management of locoregional melanoma: under the auspices of the ESMO Guidelines Committee. <i>Annals of Oncology</i> , 2020 , 31, 1449-1461	10.3	19
377	Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma. <i>New England Journal of Medicine</i> , 2020 , 383, 1139-1148	59.2	105
376	The evolving field of Dermato-oncology and the role of dermatologists: Position Paper of the EADO, EADV and Task Forces, EDF, IDS, EBDV-UEMS and EORTC Cutaneous Lymphoma Task Force. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020 , 34, 2183-2197	4.6	10
375	Dose escalation phase 1 study of radiotherapy in combination with anti-cytotoxic-T-lymphocyte-associated antigen 4 monoclonal antibody ipilimumab in patients with metastatic melanoma 2020 , 8,		7
374	Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3925-3936	2.2	78
373	Is it melanoma? Ask my dog!. <i>Melanoma Research</i> , 2020 , 30, 529-530	3.3	
372	Systemic Therapy for Melanoma: ASCO Guideline. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3947-3970	2.2	82
371	BRAF exon 11 mutant melanoma and sensitivity to BRAF/MEK inhibition: Two case reports. <i>European Journal of Cancer</i> , 2019 , 121, 109-112	7.5	1
370	Upregulation of intratumoral HLA class I and peritumoral Mx1 in ulcerated melanomas. <i>Oncolimmunology</i> , 2019 , 8, e1660121	7.2	2
369	Five-year outcomes from a phase 3 METRIC study in patients with BRAF V600E/K-mutant advanced or metastatic melanoma. <i>European Journal of Cancer</i> , 2019 , 109, 61-69	7.5	18
368	Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. <i>Annals of Oncology</i> , 2019 , 30, 582-588	10.3	325
367	Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study. <i>Lancet Oncology, The</i> , 2019 , 20, 1083-1097	21.7	356
366	Evaluation of the efficacy of immunotherapy for non-resectable mucosal melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2019 , 68, 1171-1178	7.4	28

365	Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma. <i>New England Journal of Medicine</i> , 2019 , 381, 626-636	59.2	489
364	Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma. <i>European Journal of Cancer</i> , 2019 , 116, 148-157	7.5	42
363	Melanoma during fingolimod treatment for multiple sclerosis. <i>European Journal of Cancer</i> , 2019 , 113, 75-77	7.5	8
362	Genomic Features of Exceptional Response in Vemurafenib + Cobimetinib-treated Patients with -mutated Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2019 , 25, 3239-3246	12.9	23
361	Familial predisposition to TP53/complex karyotype MDS and leukemia in DNA repair-deficient xeroderma pigmentosum. <i>Blood</i> , 2019 , 133, 2718-2724	2.2	19
360	Patient-reported outcomes in patients with resected, high-risk melanoma with BRAF or BRAF mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , 2019 , 20, 701-710	21.7	23
359	Reply to E. Hindi and K.R. Hess. <i>Journal of Clinical Oncology</i> , 2019 , 37, 1356-1358	2.2	1
358	Adverse events 2.0-Let us get SERIOs: New reporting for adverse event outcomes needed in the era of immuno-oncology. <i>European Journal of Cancer</i> , 2019 , 112, 29-31	7.5	12
357	Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial. <i>Journal of Clinical Oncology</i> , 2019 , 37, 867-875	2.2	135
356	Post-shingles granulomatous dermatosis related to anti-programmed cell death 1. <i>Immunotherapy</i> , 2019 , 11, 591-598	3.8	5
355	Neurotoxicity induced by targeted therapies in patients treated for metastatic melanoma. <i>European Journal of Cancer</i> , 2019 , 111, 8-11	7.5	0
354	Mitochondrial myopathy associated with anti-programmed cell death 1 therapy. <i>European Journal of Cancer</i> , 2019 , 110, 71-73	7.5	
353	Drug-induced lupus erythematosus following immunotherapy with anti-programmed death-(ligand) 1. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, e67	2.4	31
352	Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial. <i>European Journal of Cancer</i> , 2019 , 119, 1-10	7.5	79
351	Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease: A Nationwide, Multicenter Cohort Study. <i>Arthritis and Rheumatology</i> , 2019 , 71, 2100-2111	9.5	116
350	Risk-based stratification in head and neck mucosal melanoma. <i>Oral Oncology</i> , 2019 , 97, 44-49	4.4	12
349	Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management. <i>European Journal of Cancer</i> , 2019 , 119, 97-106	7.5	27
348	Acute pancreatitis after vismodegib for basal cell carcinoma: a causal relation?. <i>European Journal of Cancer</i> , 2019 , 118, 67-69	7.5	0

347	Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. <i>Lancet Oncology, The</i> , 2019 , 20, 1239-1251	21.7	425
346	Prognostic and theranostic 18F-FDG PET biomarkers for anti-PD1 immunotherapy in metastatic melanoma: association with outcome and transcriptomics. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019 , 46, 2298-2310	8.8	55
345	Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. <i>Lancet Oncology, The</i> , 2019 , 20, e378-e389	21.7	88
344	Adverse event (AE) kinetics in patients (pts) treated with dabrafenib + trametinib (D + T) in the metastatic and adjuvant setting. <i>Annals of Oncology</i> , 2019 , 30, v543-v544	10.3	2
343	Ipilimumab versus placebo after complete resection of stage III melanoma: Long-term follow-up results the EORTC 18071 double-blind phase 3 randomized trial.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 2512-2512	2.2	13
342	The antiPD-1 antibody spartalizumab (S) in combination with dabrafenib (D) and trametinib (T) in previously untreated patients (pts) with advanced BRAF V600E mutant melanoma: Updated efficacy and safety from parts 1 and 2 of COMBI-i.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 9531-9531	2.2	26
341	Dermatological Complications of Systemic Therapies for Melanoma 2019 , 1-22		
340	Adjuvant therapy versus watch-and-wait post surgery for stage III melanoma: a multicountry retrospective chart review. <i>Melanoma Management</i> , 2019 , 6, MMT33	2.1	2
339	One or Two Immune Checkpoint Inhibitors?. <i>Cancer Cell</i> , 2019 , 36, 579-581	24.3	8
338	An epitranscriptomic mechanism underlies selective mRNA translation remodelling in melanoma persister cells. <i>Nature Communications</i> , 2019 , 10, 5713	17.4	28
337	Evolution and recurrence of gastrointestinal immune-related adverse events induced by immune checkpoint inhibitors. <i>European Journal of Cancer</i> , 2019 , 106, 106-114	7.5	30
336	Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial. <i>JAMA Oncology</i> , 2019 , 5, 187-194	13.4	173
335	Reply to: "Acute liver failure due to immune-mediated hepatitis successfully managed with plasma exchange: New settings call for new treatment strategies?". <i>Journal of Hepatology</i> , 2019 , 70, 566-567	13.4	1
334	Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study. <i>Lancet Haematology,the</i> , 2019 , 6, e48-e57	14.6	109
333	Long-Term Survival in Patients Responding to Anti-PD-1/PD-L1 Therapy and Disease Outcome upon Treatment Discontinuation. <i>Clinical Cancer Research</i> , 2019 , 25, 946-956	12.9	67
332	Asymmetric Acral Sparing Phenomenon Related to Systemic Anticancer Therapies. <i>Skin Appendage Disorders</i> , 2018 , 4, 315-319	1.4	6
331	Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab. <i>Clinical Cancer Research</i> , 2018 , 24, 4960-4967	12.9	142
330	Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma. <i>New England Journal of Medicine</i> , 2018 , 378, 1789-1801	59.2	918

329	Risk stratification of sentinel node-positive melanoma patients defines surgical management and adjuvant therapy treatment considerations. <i>European Journal of Cancer</i> , 2018 , 96, 25-33	7.5	50
328	Sentinel lymph node biopsy in 33 non-melanoma skin cancers of the head and neck: A twelve-year experience with long-term follow-up. <i>Clinical Otolaryngology</i> , 2018 , 43, 1148-1152	1.8	2
327	Pulmonary nodules and immunotherapy: disease progression or toxicity of anti-PD1/anti-PDL1 checkpoint inhibitors?. <i>European Journal of Cancer</i> , 2018 , 93, 144-146	7.5	3
326	Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors. <i>Journal of Hepatology</i> , 2018 , 68, 1181-1190	13.4	222
325	Tolerance and outcomes of stereotactic radiosurgery combined with anti-programmed cell death-1 (pembrolizumab) for melanoma brain metastases. <i>Melanoma Research</i> , 2018 , 28, 111-119	3.3	39
324	Severe ophthalmoplegia and myocarditis following the administration of pembrolizumab. <i>European Journal of Cancer</i> , 2018 , 91, 171-173	7.5	19
323	Arterial thrombosis and anti-PD-1 blockade. <i>European Journal of Cancer</i> , 2018 , 91, 164-166	7.5	20
322	Melanoma: Immunotherapy in Advanced Melanoma and in the Adjuvant Setting 2018 , 579-591		
321	Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease. <i>European Journal of Cancer</i> , 2018 , 91, 21-29	7.5	158
320	Management of Sentinel-Node Metastasis in Melanoma. <i>New England Journal of Medicine</i> , 2018 , 378, 85-88	59.2	6
319	Longitudinal subungual acanthoma: one denomination for various clinical presentations. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018 , 32, 1608-1613	4.6	10
318	Sentinel lymph node biopsy in cutaneous head and neck melanoma. <i>European Archives of Oto-Rhino-Laryngology</i> , 2018 , 275, 1271-1279	3.5	11
317	Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. <i>Lancet Oncology</i> , 2018 , 19, 603-615	21.7	451
316	Dermatologic Side Effects of Systemic Targeted Anticancer Therapy 2018 , 285-313		
315	Estimating causal effects of time-dependent exposures on a binary endpoint in a high-dimensional setting. <i>BMC Medical Research Methodology</i> , 2018 , 18, 67	4.7	0
314	Older melanoma patients aged 75 and above retain responsiveness to anti-PD1 therapy: results of a retrospective single-institution cohort study. <i>Cancer Immunology, Immunotherapy</i> , 2018 , 67, 1571-1578	7.4	23
313	Reply to: "Immune-related hepatitis with immunotherapy: Are corticosteroids always needed?". <i>Journal of Hepatology</i> , 2018 , 69, 550-551	13.4	0
312	Reply to: "Mortality due to immunotherapy related hepatitis". <i>Journal of Hepatology</i> , 2018 , 69, 978-979	13.4	

311	Adjuvant Pembrolizumab in Resected Stage III Melanoma. <i>New England Journal of Medicine</i> , 2018 , 379, 593-595	59.2	22
310	Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial. <i>European Journal of Cancer</i> , 2018 , 101, 236-243	7.5	59
309	Enterocolitis due to immune checkpoint inhibitors: a systematic review. <i>Gut</i> , 2018 , 67, 2056-2067	19.2	109
308	4-year survival and outcomes after cessation of pembrolizumab (pembro) after 2-years in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in KEYNOTE-006.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 9503-9503	2.2	60
307	5-year survival outcomes in patients (pts) with advanced melanoma treated with pembrolizumab (pembro) in KEYNOTE-001.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 9516-9516	2.2	24
306	Effect on health-related quality of life (HRQOL) of adjuvant treatment (tx) with dabrafenib plus trametinib (D + T) in patients (pts) with resected stage III BRAF-mutant melanoma.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 9590-9590	2.2	7
305	Discovery of Iminobenzimidazole Derivatives as Novel Cytotoxic Agents. <i>Open Medicinal Chemistry Journal</i> , 2018 , 12, 74-83	1.2	
304	Eighth American Joint Committee on Cancer (AJCC) melanoma classification: Let us reconsider stage III. <i>European Journal of Cancer</i> , 2018 , 91, 168-170	7.5	23
303	New Era in the Management of Melanoma Brain Metastases. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018 , 38, 741-750	7.1	28
302	Health-related quality-of-life results for pembrolizumab versus placebo after complete resection of high-risk stage III melanoma from the EORTC 1325-MG/Keynote 054 trial: An international randomized double-blind phase III trial. <i>Annals of Oncology</i> , 2018 , 29, viii456	10.3	5
301	Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2018 , 36, 1668-1674	2.2	210
300	Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected V600-Mutant Stage III Melanoma. <i>Journal of Clinical Oncology</i> , 2018 , 36, 3441-3449	2.2	137
299	Adverse events (AEs) over time in patients (pts) treated with adjuvant dabrafenib plus trametinib (D + T) or placebo (Pbo) in the COMBI-AD trial. <i>Annals of Oncology</i> , 2018 , 29, viii446	10.3	2
298	Gender-related challenges facing oncologists: the results of the ESMO Women for Oncology Committee survey. <i>ESMO Open</i> , 2018 , 3, e000422	6	30
297	Association of homogeneous inflamed gene signature with a better outcome in patients with metastatic melanoma treated with MAGE-A3 immunotherapeutic. <i>ESMO Open</i> , 2018 , 3, e000384	6	0
296	Elevated Levels of Mutant Circulating Tumor DNA and Circulating Hepatocyte Growth Factor Are Associated With Poor Prognosis in Patients With Metastatic Melanoma.. <i>JCO Precision Oncology</i> , 2018 , 2, 1-17	3.6	2
295	Is earlier better for melanoma checkpoint blockade?. <i>Nature Medicine</i> , 2018 , 24, 1645-1648	50.5	21
294	Anticancer Therapies 2018 , 604-616		

293	Reply to: "Incidence of grade 3-4 liver injury under immune checkpoints inhibitors: A retrospective study". <i>Journal of Hepatology</i> , 2018 , 69, 1397-1398	13.4	1
292	Report on the status of women occupying leadership roles in oncology. <i>ESMO Open</i> , 2018 , 3, e000423	6	17
291	Starting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT). <i>Annals of Oncology</i> , 2018 , 29, 2163-2174	10.3	88
290	Translational control of tumor immune escape via the eIF4F-STAT1-PD-L1 axis in melanoma. <i>Nature Medicine</i> , 2018 , 24, 1877-1886	50.5	109
289	Boosting Immunity by Targeting Post-translational Prenylation of Small GTPases. <i>Cell</i> , 2018 , 175, 901-903	36.2	3
288	Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006. <i>British Journal of Cancer</i> , 2018 , 119, 670-674	8.7	60
287	Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology, The</i> , 2018 , 19, 1315-1327	21.7	291
286	The new era of adjuvant therapies for melanoma. <i>Nature Reviews Clinical Oncology</i> , 2018 , 15, 535-536	19.4	54
285	The impact of patient characteristics and disease-specific factors on first-line treatment decisions for BRAF-mutated melanoma: results from a European expert panel study. <i>Melanoma Research</i> , 2018 , 28, 333-340	3.3	10
284	Pregnancy and melanoma: a European-wide survey to assess current management and a critical literature overview. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017 , 31, 65-69	4.6	12
283	Inflammatory bowel disease and cancer response due to anti-CTLA-4: is it in the flora?. <i>Seminars in Immunopathology</i> , 2017 , 39, 327-331	12	16
282	Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial. <i>Lancet Oncology, The</i> , 2017 , 18, 393-403	21.7	69
281	Timing of completion lymphadenectomy after positive sentinel node biopsy in patients with melanoma. <i>British Journal of Surgery</i> , 2017 , 104, 726-733	5.3	5
280	Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. <i>Annals of Oncology</i> , 2017 , 28, 1631-1639	10.3	361
279	Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic -Mutant Melanoma. <i>Clinical Cancer Research</i> , 2017 , 23, 5339-5348	12.9	101
278	Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials. <i>European Journal of Cancer</i> , 2017 , 82, 45-55	7.5	114
277	Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management. <i>Cancer Treatment Reviews</i> , 2017 , 58, 70-76	14.4	173
276	Dabrafenib plus trametinib in patients with BRAF-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. <i>Lancet Oncology, The</i> , 2017 , 18, 863-873	21.7	389

275	Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. <i>Annals of Oncology</i> , 2017 , 28, 1368-1379	10.3	551
274	Promises and challenges for the implementation of computational medical imaging (radiomics) in oncology. <i>Annals of Oncology</i> , 2017 , 28, 1191-1206	10.3	314
273	Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial. <i>Lancet Oncology, The</i> , 2017 , 18, 611-622	21.7	306
272	Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2017 , 35, 785-792	2.2	696
271	Targeting autophagy inhibits melanoma growth by enhancing NK cells infiltration in a CCL5-dependent manner. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017 , 114, E9271-E9279	11.5	115
270	Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma. <i>European Journal of Cancer</i> , 2017 , 86, 115-124	7.5	49
269	Inflammatory gastrointestinal diseases associated with PD-1 blockade antibodies. <i>Annals of Oncology</i> , 2017 , 28, 2860-2865	10.3	71
268	Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group 2017 , 5, 95		999
267	Characterization of complete responses (CRs) in patients with advanced melanoma (MEL) who received the combination of nivolumab (NIVO) and ipilimumab (IPI), NIVO or IPI alone. <i>Annals of Oncology</i> , 2017 , 28, v428	10.3	22
266	Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3807-3814	2.2	264
265	Melanoma-associated fibroblasts decrease tumor cell susceptibility to NK cell-mediated killing through matrix-metalloproteinases secretion. <i>Oncotarget</i> , 2017 , 8, 19780-19794	3.3	63
264	Survival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017. <i>European Journal of Cancer</i> , 2017 , 83, 247-257	7.5	181
263	Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma. <i>New England Journal of Medicine</i> , 2017 , 377, 1813-1823	59.2	778
262	P53 and MITF/Bcl-2 identified as key pathways in the acquired resistance of NRAS-mutant melanoma to MEK inhibition. <i>European Journal of Cancer</i> , 2017 , 83, 154-165	7.5	32
261	Colon Immune-Related Adverse Events: Anti-CTLA-4 and Anti-PD-1 Blockade Induce Distinct Immunopathological Entities. <i>Journal of Crohns and Colitis</i> , 2017 , 11, 1238-1246	1.5	79
260	Clinical outcomes after interstitial brachytherapy for early-stage nasal squamous cell carcinoma. <i>Brachytherapy</i> , 2017 , 16, 1021-1027	2.4	6
259	Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study. <i>Annals of Oncology</i> , 2017 , 28, 2581-2587	10.3	129
258	Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). <i>Lancet, The</i> , 2017 , 390, 1853-1862	40	703

257	Safety and immunogenicity of MAGE-A3 cancer immunotherapeutic with dacarbazine in patients with MAGE-A3-positive metastatic cutaneous melanoma: an open phase I/II study with a first assessment of a predictive gene signature. <i>ESMO Open</i> , 2017 , 2, e000203	6	11
256	Checkpoint Blockade Plus Oncolytic Virus: A Hot Therapeutic Cancer Strategy. <i>Trends in Molecular Medicine</i> , 2017 , 23, 983-985	11.5	7
255	Successful re-challenge with anti-BRAF and anti-MEK in a patient with symptomatic melanoma flare. <i>European Journal of Cancer</i> , 2017 , 82, 25-26	7.5	2
254	Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1/anti-Programmed cell Death-Ligand 1 agents: A single-centre pharmacovigilance database analysis. <i>European Journal of Cancer</i> , 2017 , 82, 34-44	7.5	110
253	Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2017 , 28, iv119-iv142	10.3	1100
252	Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression: Analysis of 2 Phase 3 Clinical Trials. <i>JAMA Oncology</i> , 2017 , 3, 1511-1519	13.4	101
251	Molecular Pathways: The eIF4F Translation Initiation Complex-New Opportunities for Cancer Treatment. <i>Clinical Cancer Research</i> , 2017 , 23, 21-25	12.9	48
250	Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody. <i>Clinical Cancer Research</i> , 2017 , 23, 1929-1936	12.9	181
249	A Novel Spectroscopically Determined Pharmacodynamic Biomarker for Skin Toxicity in Cancer Patients Treated with Targeted Agents. <i>Cancer Research</i> , 2017 , 77, 557-565	10.1	5
248	Melanoma cutáneo cervicofacial. <i>EMC - Otorrinolaringología</i> , 2017 , 46, 1-9	0	
247	Melanomi cutanei cervicofacciali. <i>EMC - Otorinolaringoiatria</i> , 2017 , 16, 1-9	0	
246	Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma. <i>European Journal of Cancer</i> , 2017 , 86, 37-45	7.5	106
245	Systemic Therapy Options for Patients With Unresectable Melanoma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017 , 37, 661-672	7.1	5
244	Acute Lower Limb Ischaemia and Diabetes in a Patient Treated with Anti-PD1 Monoclonal Antibody for Metastatic Melanoma. <i>Acta Dermato-Venereologica</i> , 2017 , 97, 408-409	2.2	15
243	P315 Gastrointestinal immune related adverse events associated with programmed-Death 1 blockade. <i>Journal of Crohns and Colitis</i> , 2017 , 11, S237-S237	1.5	10
242	Long-term outcomes in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in the phase 3 KEYNOTE-006 study who completed pembrolizumab (pembro) treatment.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 9504-9504	2.2	40
241	Transcriptional response to hypoxic stress in melanoma and prognostic potential of GBE1 and BNIP3. <i>Oncotarget</i> , 2017 , 8, 108786-108801	3.3	18
240	Immune Checkpoint Inhibitors in Melanoma Define a New Era in Immunotherapy Aiming for Cure 2017 , 427-436		

239	Renal effects of immune checkpoint inhibitors. <i>Nephrology Dialysis Transplantation</i> , 2017 , 32, 936-942	4.3	48
238	Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab. <i>JAMA Dermatology</i> , 2016 , 152, 45-51	5.1	414
237	Synergistic effects of eIF4A and MEK inhibitors on proliferation of NRAS-mutant melanoma cell lines. <i>Cell Cycle</i> , 2016 , 15, 2405-9	4.7	8
236	Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. <i>Lancet Oncology</i> , 2016 , 17, 1558-1568	21.7	627
235	Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials. <i>Lancet Oncology</i> , 2016 , 17, 1743-1754	21.7	205
234	PD-L1 expression as a biomarker for nivolumab (NIVO) plus ipilimumab (IPI) and NIVO alone in advanced melanoma (MEL): A pooled analysis. <i>Annals of Oncology</i> , 2016 , 27, vi381	10.3	11
233	Three-year estimate of overall survival in COMBI-v, a randomized phase 3 study evaluating first-line dabrafenib (D) + trametinib (T) in patients (pts) with unresectable or metastatic BRAF V600E/K mutant cutaneous melanoma. <i>Annals of Oncology</i> , 2016 , 27, vi575	10.3	26
232	Melanoma and immunotherapy bridge 2015 : Naples, Italy. 1-5 December 2015. <i>Journal of Translational Medicine</i> , 2016 , 14, 65	8.5	8
231	Mechanisms of skin aging induced by EGFR inhibitors. <i>Supportive Care in Cancer</i> , 2016 , 24, 4241-8	3.9	17
230	Immune-related adverse events with immune checkpoint blockade: a comprehensive review. <i>European Journal of Cancer</i> , 2016 , 54, 139-148	7.5	1239
229	Cancer Immunotherapy with Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel Disease. <i>Journal of Crohns and Colitis</i> , 2016 , 10, 395-401	1.5	184
228	Severe cutaneous adverse reaction associated with vemurafenib: DRESS, AGEP or overlap reaction?. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016 , 30, 178-9	4.6	23
227	Secondary Tumors Arising in Patients Undergoing BRAF Inhibitor Therapy Exhibit Increased BRAF-CRAF Heterodimerization. <i>Cancer Research</i> , 2016 , 76, 1476-84	10.1	32
226	Impact of Skin Toxicities Associated with Targeted Cancer Therapies on Body Image: A Prospective Study. <i>Clinical Drug Investigation</i> , 2016 , 36, 235-42	3.2	1
225	Two cases of immune thrombocytopenia associated with pembrolizumab. <i>European Journal of Cancer</i> , 2016 , 54, 172-174	7.5	47
224	Doxycycline for prevention of erlotinib-induced rash in patients with non-small-cell lung cancer (NSCLC) after failure of first-line chemotherapy: A randomized, open-label trial. <i>Journal of the American Academy of Dermatology</i> , 2016 , 74, 1077-85	4.5	24
223	Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab. <i>Journal of Clinical Oncology</i> , 2016 , 34, 1510-7	2.2	509
222	Survival of patients with advanced metastatic melanoma: The impact of novel therapies. <i>European Journal of Cancer</i> , 2016 , 53, 125-34	7.5	115

221	Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. <i>Annals of Oncology</i> , 2016 , 27, 559-74	10.3	548
220	Challenges of phase 1 clinical trials evaluating immune checkpoint-targeted antibodies. <i>Annals of Oncology</i> , 2016 , 27, 214-24	10.3	67
219	Three-year overall survival for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 9503-9503	2.2	66
218	Pembrolizumab versus ipilimumab for advanced melanoma: Final overall survival analysis of KEYNOTE-006.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 9504-9504	2.2	32
217	Pooled analysis of safety over time and link between adverse events and efficacy across combination dabrafenib and trametinib (D+T) registration trials.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 9534-9534	2.2	5
216	The interval between primary melanoma excision and sentinel node biopsy is not associated with survival in sentinel node positive patients - An EORTC Melanoma Group study. <i>European Journal of Surgical Oncology</i> , 2016 , 42, 1906-1913	3.6	21
215	Compounds Triggering ER Stress Exert Anti-Melanoma Effects and Overcome BRAF Inhibitor Resistance. <i>Cancer Cell</i> , 2016 , 29, 805-819	24.3	110
214	Impact of dermatologic adverse events induced by targeted therapies on quality of life. <i>Critical Reviews in Oncology/Hematology</i> , 2016 , 101, 158-68	7	9
213	Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma. <i>JAMA - Journal of the American Medical Association</i> , 2016 , 315, 1600-9	27.4	666
212	Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. <i>Nature Reviews Clinical Oncology</i> , 2016 , 13, 473-86	19.4	591
211	Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma. <i>European Journal of Cancer</i> , 2016 , 67, 46-54	7.5	54
210	Effect of nivolumab on health-related quality of life in patients with treatment-naïve advanced melanoma: results from the phase III CheckMate 066 study. <i>Annals of Oncology</i> , 2016 , 27, 1940-6	10.3	67
209	Cutaneous malignant melanoma in children and adolescents treated in pediatric oncology units. <i>Pediatric Blood and Cancer</i> , 2016 , 63, 1922-7	3	17
208	Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy. <i>New England Journal of Medicine</i> , 2016 , 375, 1845-1855	59.2	870
207	Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma. <i>Journal of Clinical Oncology</i> , 2016 , 34, 4102-4109	2.2	400
206	Rapid and objective CT scan prognostic scoring identifies metastatic patients with long-term clinical benefit on anti-PD-1/L1 therapy. <i>European Journal of Cancer</i> , 2016 , 65, 33-42	7.5	39
205	Nivolumab in previously untreated melanoma without BRAF mutation. <i>New England Journal of Medicine</i> , 2015 , 372, 320-30	59.2	3809
204	Effect of time to sentinel-node biopsy on the prognosis of cutaneous melanoma. <i>European Journal of Cancer</i> , 2015 , 51, 1780-93	7.5	21

203	Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. <i>Lancet Oncology, The</i> , 2015 , 16, 908-18	21.7	1151
202	Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma. <i>European Journal of Cancer</i> , 2015 , 51, 833-40	7.5	60
201	Pembrolizumab versus Ipilimumab in Advanced Melanoma. <i>New England Journal of Medicine</i> , 2015 , 372, 2521-32	59.2	3792
200	Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. <i>New England Journal of Medicine</i> , 2015 , 372, 2006-17	59.2	2001
199	A randomized controlled comparison of pembrolizumab and chemotherapy in patients with ipilimumab-refractory melanoma. <i>Journal of Translational Medicine</i> , 2015 , 13, O5	8.5	20
198	Nivolumab improved survival vs dacarbazine in patients with untreated advanced melanoma. <i>Journal of Translational Medicine</i> , 2015 , 13, O6	8.5	9
197	Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2015 , 33, 1889-94	2.2	1425
196	Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. <i>Lancet Oncology, The</i> , 2015 , 16, 522-30	21.7	842
195	Five-year survival rates for treatment-naïve patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial. <i>Journal of Clinical Oncology</i> , 2015 , 33, 1191-6	2.2	334
194	Who benefits most from adjuvant interferon treatment for melanoma?. <i>American Journal of Therapeutics</i> , 2015 , 22, 54-60	1	12
193	Treatment algorithms in stage IV melanoma. <i>American Journal of Therapeutics</i> , 2015 , 22, 61-7	1	9
192	Side effects and toxicities of targeted therapies in stage IV melanoma. <i>American Journal of Therapeutics</i> , 2015 , 22, 44-53	1	7
191	Efficacy of neoadjuvant cetuximab alone or with platinum salt for the treatment of unresectable advanced nonmetastatic cutaneous squamous cell carcinomas. <i>British Journal of Dermatology</i> , 2015 , 173, 527-34	4	47
190	Nail toxicities induced by systemic anticancer treatments. <i>Lancet Oncology, The</i> , 2015 , 16, e181-9	21.7	109
189	Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial. <i>Lancet Oncology, The</i> , 2015 , 16, 1389-98	21.7	162
188	A randomized, controlled phase III trial of nab-Paclitaxel versus dacarbazine in chemotherapy-naïve patients with metastatic melanoma. <i>Annals of Oncology</i> , 2015 , 26, 2267-74	10.3	49
187	Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. <i>Science</i> , 2015 , 350, 1079-84	33.3	1689
186	New Functional Signatures for Understanding Melanoma Biology from Tumor Cell Lineage-Specific Analysis. <i>Cell Reports</i> , 2015 , 13, 840-853	10.6	48

185	Sun exposure profile in the French population. Results of the EDIFICE Melanoma survey. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015 , 29 Suppl 2, 6-10	4.6	10
184	Immune Checkpoint Inhibitors. <i>Progress in Tumor Research</i> , 2015 , 42, 55-66		93
183	Improved overall survival in melanoma with combined dabrafenib and trametinib. <i>New England Journal of Medicine</i> , 2015 , 372, 30-9	59.2	1723
182	3301 Two year estimate of overall survival in COMBI-v, a randomized, open-label, phase III study comparing the combination of dabrafenib (D) and trametinib (T) with vemurafenib (Vem) as first-line therapy in patients (pts) with unresectable or metastatic BRAF V600E/K mutation-positive cutaneous melanoma. <i>European Journal of Cancer</i> , 2015 , 51, S663	7.5	44
181	EDIFICE Melanoma survey: knowledge and attitudes on melanoma prevention and diagnosis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015 , 29 Suppl 2, 11-5	4.6	6
180	Comparison of sun protection modalities in parents and children. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015 , 29 Suppl 2, 16-9	4.6	11
179	Evolution of sun-protection measures for children. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015 , 29 Suppl 2, 20-2	4.6	7
178	Personal vs. intrinsic melanoma risk awareness: results of the EDIFICE Melanoma survey. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015 , 29 Suppl 2, 31-4	4.6	2
177	Melanoma risk-takers: fathers and sons. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015 , 29 Suppl 2, 35-8	4.6	3
176	Bioactive Flavaglines: Synthesis and Pharmacology 2015 , 171-198		1
175	Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. <i>Lancet, The</i> , 2015 , 386, 444-51	40	926
174	Development of Novel Anticancer Agents that Target Prohibitins and the Translation Initiation Factor eIF4A. <i>Annals of Oncology</i> , 2015 , 26, ii25	10.3	
173	Prevalence of sunbed use, and characteristics and knowledge of sunbed users: results from the French population-based Edifice Melanoma survey. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015 , 29 Suppl 2, 23-30	4.6	30
172	Immune checkpoint inhibitors in melanoma provide the cornerstones for curative therapies. <i>Seminars in Oncology</i> , 2015 , 42, 429-35	5.5	57
171	Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25. <i>Cell Research</i> , 2015 , 25, 208-24	24.7	126
170	Expanded access programmes: patient interests versus clinical trial integrity. <i>Lancet Oncology, The</i> , 2015 , 16, 15-7	21.7	9
169	Phase I study combining anti-PD-L1 (MEDI4736) with BRAF (dabrafenib) and/or MEK (trametinib) inhibitors in advanced melanoma.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3003-3003	2.2	94
168	Clinical response, progression-free survival (PFS), and safety in patients (pts) with advanced melanoma (MEL) receiving nivolumab (NIVO) combined with ipilimumab (IPI) vs IPI monotherapy in CheckMate 069 study.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 9004-9004	2.2	14

167	Long-term efficacy of pembrolizumab (pembro; MK-3475) in a pooled analysis of 655 patients (pts) with advanced melanoma (MEL) enrolled in KEYNOTE-001.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 9005-9005	2.2	40
166	Safety profile of nivolumab (NIVO) in patients (pts) with advanced melanoma (MEL): A pooled analysis.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 9018-9018	2.2	56
165	Patient-reported outcomes (PROs) in KEYNOTE-002, a randomized study of pembrolizumab vs chemotherapy in patients (pts) with ipilimumab-refractory (IPI-R) metastatic melanoma (MEL).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 9040-9040	2.2	2
164	Seminal vesicle metastasis of cutaneous malignant melanoma: An unusual and challenging presentation. <i>Canadian Urological Association Journal</i> , 2015 , 9, E220-3	1.2	2
163	Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. <i>Nature</i> , 2014 , 508, 118-22	50.4	550
162	Dramatic response to radiotherapy combined with vemurafenib. Is vemurafenib a radiosensitizer?. <i>European Journal of Dermatology</i> , 2014 , 24, 265-7	0.8	5
161	MÉastase sous-cutané jugale de mlanome malin. <i>Annales Francaises DKOto-Rhino-Laryngologie Et De Pathologie Cervico-Faciale</i> , 2014 , 131, 176-178	0	
160	Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. <i>Lancet, The</i> , 2014 , 384, 1109-17	40	1340
159	Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. <i>New England Journal of Medicine</i> , 2014 , 371, 1877-88	59.2	1195
158	elF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies. <i>Nature</i> , 2014 , 513, 105-9	50.4	237
157	Sorafenib plus dacarbazine in solid tumors: a phase I study with dynamic contrast-enhanced ultrasonography and genomic analysis of sequential tumor biopsy samples. <i>Investigational New Drugs</i> , 2014 , 32, 312-22	4.3	6
156	Kidney injuries related to ipilimumab. <i>Investigational New Drugs</i> , 2014 , 32, 769-73	4.3	118
155	Molecular characterization and patient outcome of melanoma nodal metastases and an unknown primary site. <i>Annals of Surgical Oncology</i> , 2014 , 21, 4317-23	3.1	15
154	Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. <i>Lancet Oncology, The</i> , 2014 , 15, 323-32	21.7	753
153	P202 Ipilimumab colitis: a GETAID multicentric study. <i>Journal of Crohns and Colitis</i> , 2014 , 8, S146	1.5	2
152	Hypodermal metastasis of malignant melanoma to the cheek. <i>European Annals of Otorhinolaryngology, Head and Neck Diseases</i> , 2014 , 131, 189-91	2.2	
151	Pembrolizumab (Pembro; Mk-3475) for Advanced Melanoma (Mel): Randomized Comparison of Two Dosing Schedules. <i>Annals of Oncology</i> , 2014 , 25, v1	10.3	15
150	Harnessing the immune system to provide long-term survival in patients with melanoma and other solid tumors. <i>Oncolmunology</i> , 2014 , 3, e27560	7.2	34

149	Molecular pathology of cutaneous melanoma. <i>Melanoma Management</i> , 2014 , 1, 151-164	2.1	3
148	Functional and symptom impact of trametinib versus chemotherapy in BRAF V600E advanced or metastatic melanoma: quality-of-life analyses of the METRIC study. <i>Annals of Oncology</i> , 2014 , 25, 700-706	10.3	40
147	Regulation of CD4(+)NKG2D(+) Th1 cells in patients with metastatic melanoma treated with sorafenib: role of IL-15R β and NKG2D triggering. <i>Cancer Research</i> , 2014 , 74, 68-80	10.1	33
146	Correlation of phenotype/genotype in a cohort of 23 xeroderma pigmentosum-variant patients reveals 12 new disease-causing POLH mutations. <i>Human Mutation</i> , 2014 , 35, 117-28	4.7	28
145	PD-1 blockade induces responses by inhibiting adaptive immune resistance. <i>Nature</i> , 2014 , 515, 568-71	50.4	4014
144	Vemurafenib cooperates with HPV to promote initiation of cutaneous tumors. <i>Cancer Research</i> , 2014 , 74, 2238-45	10.1	26
143	Cutaneous melanoma. <i>Lancet, The</i> , 2014 , 383, 816-27	40	379
142	Surrogate endpoints for overall survival in metastatic melanoma: a meta-analysis of randomised controlled trials. <i>Lancet Oncology, The</i> , 2014 , 15, 297-304	21.7	49
141	Randomized comparison of two doses of the anti-PD-1 monoclonal antibody MK-3475 for ipilimumab-refractory (IPI-R) and IPI-naive (IPI-N) melanoma (MEL).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3000-3000	2.2	9
140	Baseline tumor size as an independent prognostic factor for overall survival in patients with metastatic melanoma treated with the anti-PD-1 monoclonal antibody MK-3475.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3015-3015	2.2	17
139	Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL).. <i>Journal of Clinical Oncology</i> , 2014 , 32, LBA9000-LBA9000	2.2	18
138	Ipilimumab versus placebo after complete resection of stage III melanoma: Initial efficacy and safety results from the EORTC 18071 phase III trial.. <i>Journal of Clinical Oncology</i> , 2014 , 32, LBA9008-LBA9008	2.2	13
137	Melanome Thérapeutique par les médicaments : anticorps anti-CTLA-4 et anti-PD1. <i>Bulletin De L'Académie Nationale De Médecine</i> , 2014 , 198, 297-308	0.1	3
136	Molecular testing in Cutaneous Melanoma 2014 , 363-374		
135	Regulation of gap junctions in melanoma and their impact on Melan-A/MART-1-specific CD8+ T lymphocyte emergence. <i>Journal of Molecular Medicine</i> , 2013 , 91, 1207-20	5.5	6
134	Drug of the year: programmed death-1 receptor/programmed death-1 ligand-1 receptor monoclonal antibodies. <i>European Journal of Cancer</i> , 2013 , 49, 2968-71	7.5	70
133	Gene electrotransfer of plasmid antiangiogenic metargidin peptide (AMEP) in disseminated melanoma: safety and efficacy results of a phase I first-in-man study. <i>Human Gene Therapy Clinical Development</i> , 2013 , 24, 99-107	3.2	51
132	Metastatic melanoma: New paradigms of treatment and new toxicities. <i>European Journal of Cancer, Supplement</i> , 2013 , 11, 278-80	1.6	1

131	CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. <i>Clinical Cancer Research</i> , 2013 , 19, 5300-9	12.9	485
130	Vandetanib in advanced medullary thyroid cancer: review of adverse event management strategies. <i>Advances in Therapy</i> , 2013 , 30, 945-66	4.1	40
129	Targeted therapy-induced radiation recall. <i>European Journal of Cancer</i> , 2013 , 49, 1662-8	7.5	45
128	Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. <i>New England Journal of Medicine</i> , 2013 , 369, 134-44	59.2	2661
127	Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study. <i>Lancet Oncology</i> , 2013 , 14, 733-40	21.7	135
126	Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma. <i>Annals of the New York Academy of Sciences</i> , 2013 , 1291, 1-13	6.5	215
125	Phase I clinical trial combining imatinib mesylate and IL-2 in refractory cancer patients: IL-2 interferes with the pharmacokinetics of imatinib mesylate. <i>Onc Immunology</i> , 2013 , 2, e23079	7.2	16
124	Phase I clinical trial combining imatinib mesylate and IL-2: HLA-DR NK cell levels correlate with disease outcome. <i>Onc Immunology</i> , 2013 , 2, e23080	7.2	24
123	Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2013 , 31, 2413-20	2.2	163
122	Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival. <i>Annals of Oncology</i> , 2013 , 24, 1697-703	10.3	237
121	Mast cell sarcoma: a rare and aggressive entity--report of two cases and review of the literature. <i>Journal of Clinical Oncology</i> , 2013 , 31, e90-7	2.2	37
120	Update on the role of ipilimumab in melanoma and first data on new combination therapies. <i>Current Opinion in Oncology</i> , 2013 , 25, 166-72	4.2	22
119	Final results of phase III SYMMETRY study: randomized, double-blind trial of elesclomol plus paclitaxel versus paclitaxel alone as treatment for chemotherapy-naive patients with advanced melanoma. <i>Journal of Clinical Oncology</i> , 2013 , 31, 1211-8	2.2	78
118	Vemurafenib and radiosensitization. <i>JAMA Dermatology</i> , 2013 , 149, 855-7	5.1	66
117	Efficacy and safety of retreatment with ipilimumab in patients with pretreated advanced melanoma who progressed after initially achieving disease control. <i>Clinical Cancer Research</i> , 2013 , 19, 2232-9	12.9	117
116	Small Molecule Multikinase Inhibitors 2013 , 196-207		
115	Analysis of dermatologic events in vemurafenib-treated patients with melanoma. <i>Oncologist</i> , 2013 , 18, 314-22	5.7	162
114	Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients. <i>Annals of Oncology</i> , 2013 , 24, 1691-7	10.3	135

113	The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. <i>PLoS ONE</i> , 2013 , 8, e53745	3.7	343
112	Dermatologic Side Effects of Systemic Anticancer Therapy 2013 , 381-419		1
111	Advances in the management of cutaneous toxicities of targeted therapies. <i>Seminars in Oncology</i> , 2012 , 39, 227-40	5.5	31
110	Genetic variability and integration of Merkel cell polyomavirus in Merkel cell carcinoma. <i>Virology</i> , 2012 , 426, 134-42	3.6	76
109	Drug-induced Nail Changes 2012 , 413-442		
108	Severe meningo-radiculo-neuritis associated with ipilimumab. <i>Investigational New Drugs</i> , 2012 , 30, 2407-13	4.9	55
107	Melanoma in 2011: a new paradigm tumor for drug development. <i>Nature Reviews Clinical Oncology</i> , 2012 , 9, 74-6	19.4	20
106	Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991. <i>European Journal of Cancer</i> , 2012 , 48, 218-25	7.5	146
105	EORTC Melanoma Group achievements. <i>European Journal of Cancer, Supplement</i> , 2012 , 10, 112-119	1.6	
104	Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. <i>Lancet Oncology, The</i> , 2012 , 13, 1087-95	21.7	708
103	The challenge to bring personalized cancer medicine from clinical trials into routine clinical practice: the case of the Institut Gustave Roussy. <i>Molecular Oncology</i> , 2012 , 6, 204-10	7.9	15
102	Four-Year Survival Update for Metastatic Melanoma (MM) Patients (PTS) Treated with Ipilimumab (IPI) + Dacarbazine (DTIC) on Phase 3 Study CA184-024. <i>Annals of Oncology</i> , 2012 , 23, ix367	10.3	6
101	Improved survival with MEK inhibition in BRAF-mutated melanoma. <i>New England Journal of Medicine</i> , 2012 , 367, 107-14	59.2	1634
100	Visceral lesions occurring during follow-up of melanoma patients: a true place for other diagnosis than melanoma metastasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2012 , 26, 602-10	4.6	1
99	Sequential research-related biopsies in phase I trials: acceptance, feasibility and safety. <i>Annals of Oncology</i> , 2012 , 23, 1301-1306	10.3	32
98	Radiotherapy as a risk factor for malignant melanoma after childhood skin hemangioma. <i>Melanoma Research</i> , 2012 , 22, 77-85	3.3	5
97	Skin tumors induced by sorafenib; paradoxical RAS-RAF pathway activation and oncogenic mutations of HRAS, TP53, and TGFBR1. <i>Clinical Cancer Research</i> , 2012 , 18, 263-72	12.9	103
96	Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma. <i>Clinical Cancer Research</i> , 2012 , 18, 555-67	12.9	238

95	A new spectrum of skin toxic effects associated with the multikinase inhibitor vandetanib. <i>Archives of Dermatology</i> , 2012 , 148, 1418-20		42
94	Prognostic factors of paraneoplastic pemphigus. <i>Archives of Dermatology</i> , 2012 , 148, 1165-72		99
93	Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma. <i>Journal of Clinical Oncology</i> , 2012 , 30, 3810-8	2.2	204
92	RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. <i>Journal of Clinical Oncology</i> , 2012 , 30, 316-21	2.2	318
91	Targeted therapies for renal cell carcinoma: review of adverse event management strategies. <i>Journal of the National Cancer Institute</i> , 2012 , 104, 93-113	9.7	168
90	Is ulceration in cutaneous melanoma just a prognostic and predictive factor or is ulcerated melanoma a distinct biologic entity?. <i>Current Opinion in Oncology</i> , 2012 , 24, 137-40	4.2	35
89	BREAK-MB: A phase II study assessing overall intracranial response rate (OIRR) to dabrafenib (GSK2118436) in patients (pts) with BRAF V600E/k mutation-positive melanoma with brain metastases (mets).. <i>Journal of Clinical Oncology</i> , 2012 , 30, 8501-8501	2.2	16
88	Updated overall survival (OS) results for BRIM-3, a phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib (vem) with dacarbazine (DTIC) in previously untreated patients with BRAFV600E-mutated melanoma.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 8502-8502	2.2	65
87	Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. <i>New England Journal of Medicine</i> , 2011 , 364, 2517-26	59.2	3396
86	Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032). <i>European Journal of Cancer</i> , 2011 , 47, 1476-83	7.5	157
85	New drugs in melanoma: it's a whole new world. <i>European Journal of Cancer</i> , 2011 , 47, 2150-7	7.5	145
84	Management of tyrosine kinase inhibitor-induced hand-foot skin reaction: viewpoints from the medical oncologist, dermatologist, and oncology nurse. <i>The Journal of Supportive Oncology</i> , 2011 , 9, 13-23		33
83	Improved survival with vemurafenib in melanoma with BRAF V600E mutation. <i>New England Journal of Medicine</i> , 2011 , 364, 2507-16	59.2	5851
82	A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma. <i>Nature</i> , 2011 , 480, 94-8	50.4	365
81	Pharmacokinetic results of a phase I trial of sorafenib in combination with dacarbazine in patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2011 , 68, 53-61	3.5	14
80	Prognosis in patients with sentinel node-positive melanoma is accurately defined by the combined Rotterdam tumor load and Dewar topography criteria. <i>Journal of Clinical Oncology</i> , 2011 , 29, 2206-14	2.2	164
79	Senescent cells develop a PARP-1 and nuclear factor- κ B-associated secretome (PNAS). <i>Genes and Development</i> , 2011 , 25, 1245-61	12.6	168
78	Cyclophosphamide induces differentiation of Th17 cells in cancer patients. <i>Cancer Research</i> , 2011 , 71, 661-5	10.1	113

77	Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies. <i>British Journal of Cancer</i> , 2011 , 105, 353-9	8.7	39
76	Immunotherapy of Melanoma: A New Era 2011 , 359-372		
75	Dermatologic Manifestations of Systemic Oncologic Therapy of Cutaneous Malignancies 2011 , 379-385		
74	Sunitinib efficacy in the treatment of metastatic skin adnexal carcinomas: report of two patients with hidradenocarcinoma and trichoblastic carcinoma. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2010 , 24, 199-203	4.6	31
73	Management and outcome of metastatic melanoma during pregnancy. <i>British Journal of Dermatology</i> , 2010 , 162, 274-81	4	40
72	Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma. <i>Clinical Cancer Research</i> , 2010 , 16, 1042-8	12.9	201
71	Improved survival with ipilimumab in patients with metastatic melanoma. <i>New England Journal of Medicine</i> , 2010 , 363, 711-23	59.2	10591
70	Practical considerations in the management of hand-foot skin reaction caused by multikinase inhibitors. <i>Community Oncology</i> , 2010 , 7, 23-29		21
69	Breast cancer following radiotherapy for a hemangioma during childhood. <i>Cancer Causes and Control</i> , 2010 , 21, 1807-16	2.8	6
68	Anti-CTLA-4 antibody adjuvant therapy in melanoma. <i>Seminars in Oncology</i> , 2010 , 37, 455-9	5.5	33
67	What is the role of cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma?. <i>Oncologist</i> , 2009 , 14, 848-61	5.7	83
66	Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. <i>Journal of Clinical Oncology</i> , 2009 , 27, 2823-30	2.2	456
65	Gap junction communication between autologous endothelial and tumor cells induce cross-recognition and elimination by specific CTL. <i>Journal of Immunology</i> , 2009 , 182, 2654-64	5.3	25
64	Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib. <i>Oncology</i> , 2009 , 77, 257-71	3.6	143
63	Small molecules and targeted therapies in distant metastatic disease. <i>Annals of Oncology</i> , 2009 , 20 Suppl 6, vi35-40	10.3	61
62	Natural killer cell IFN-gamma levels predict long-term survival with imatinib mesylate therapy in gastrointestinal stromal tumor-bearing patients. <i>Cancer Research</i> , 2009 , 69, 3563-9	10.1	160
61	Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib. <i>Journal of Clinical Oncology</i> , 2009 , 27, e59-61	2.2	128
60	Search for evidence-based approaches for the prevention and palliation of hand-foot skin reaction (HFSR) caused by the multikinase inhibitors (MKIs). <i>Oncologist</i> , 2009 , 14, 291-302	5.7	84

59	Cutaneous side-effects in patients on long-term treatment with epidermal growth factor receptor inhibitors. <i>British Journal of Dermatology</i> , 2009 , 161, 515-21	4	94
58	Dermatologic symptoms associated with the multikinase inhibitor sorafenib. <i>Journal of the American Academy of Dermatology</i> , 2009 , 60, 299-305	4.5	114
57	Thyroid adenomas and carcinomas following radiotherapy for a hemangioma during infancy. <i>Radiotherapy and Oncology</i> , 2009 , 93, 377-82	5.3	21
56	Twenty-two cutaneous primary melanomas in a patient with high genetic predisposition to melanoma receiving levodopa therapy for Parkinson disease. <i>Pigment Cell and Melanoma Research</i> , 2009 , 22, 851-3	4.5	1
55	Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib. <i>Nephrology Dialysis Transplantation</i> , 2009 , 24, 682-5	4.3	125
54	Dendritic cell-derived exosomes promote natural killer cell activation and proliferation: a role for NKG2D ligands and IL-15Ralpha. <i>PLoS ONE</i> , 2009 , 4, e4942	3.7	286
53	Gene expression signature associated with BRAF mutations in human primary cutaneous melanomas. <i>Molecular Oncology</i> , 2008 , 1, 425-30	7.9	41
52	Comment gérer au mieux la toxicité des traitements antiangiogéniques? 2008 , 197-205		
51	Ctla-4 blockade confers lymphocyte resistance to regulatory T-cells in advanced melanoma: surrogate marker of efficacy of tremelimumab?. <i>Clinical Cancer Research</i> , 2008 , 14, 5242-9	12.9	91
50	Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor. <i>Archives of Dermatology</i> , 2008 , 144, 886-92		170
49	Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. <i>Oncologist</i> , 2008 , 13, 1001-11	5.7	273
48	Consensus guidelines for the management of radiation dermatitis and coexisting acne-like rash in patients receiving radiotherapy plus EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck. <i>Annals of Oncology</i> , 2008 , 19, 142-9	10.3	153
47	ICAM-1 has a critical role in the regulation of metastatic melanoma tumor susceptibility to CTL lysis by interfering with PI3K/AKT pathway. <i>Cancer Research</i> , 2008 , 68, 9854-64	10.1	51
46	Analysis and characterization of antitumor T-cell response after administration of dendritic cells loaded with allogeneic tumor lysate to metastatic melanoma patients. <i>Journal of Immunotherapy</i> , 2008 , 31, 101-12	5	54
45	Introduction of functional chimeric E/L-selectin by RNA electroporation to target dendritic cells from blood to lymph nodes. <i>Cancer Immunology, Immunotherapy</i> , 2008 , 57, 467-77	7.4	31
44	Tumor destruction using electrochemotherapy followed by CpG oligodeoxynucleotide injection induces distant tumor responses. <i>Cancer Immunology, Immunotherapy</i> , 2008 , 57, 1291-300	7.4	51
43	A phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma. <i>Journal of Clinical Oncology</i> , 2008 , 26, 9023-9023	2.2	12
42	AZD6244 (ARRY-142886) vs temozolomide (TMZ) in patients (pts) with advanced melanoma: An open-label, randomized, multicenter, phase II study. <i>Journal of Clinical Oncology</i> , 2008 , 26, 9033-9033	2.2	86

41	Immunization with recombinant MAGE-A3 protein combined with adjuvant systems AS15 or AS02B in patients with unresectable and progressive metastatic cutaneous melanoma: A randomized open-label phase II study of the EORTC Melanoma Group (16032- 18031). <i>Journal of Clinical Oncology</i> , 2008 , 26, 9065-9065	2.2	41
40	Long-term protective effect of mature DC-LAMP+ dendritic cell accumulation in sentinel lymph nodes containing micrometastatic melanoma. <i>Clinical Cancer Research</i> , 2007 , 13, 3825-30	12.9	59
39	Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma. <i>Clinical Cancer Research</i> , 2007 , 13, 1801-9	12.9	124
38	Primary cutaneous diffuse large B-cell lymphoma, leg type: clinicopathologic features and prognostic analysis in 60 cases. <i>Archives of Dermatology</i> , 2007 , 143, 1144-50		168
37	Angiosarcomas, a heterogeneous group of sarcomas with specific behavior depending on primary site: a retrospective study of 161 cases. <i>Annals of Oncology</i> , 2007 , 18, 2030-6	10.3	242
36	Randomized phase III study of paclitaxel plus carboplatin with or without sorafenib as second-line treatment in patients with advanced melanoma. <i>Journal of Clinical Oncology</i> , 2007 , 25, 8510-8510	2.2	38
35	Folliculitis and perionyxis associated with the EGFR inhibitor erlotinib. <i>Targeted Oncology</i> , 2006 , 1, 100-103		2
34	Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. <i>Journal of Clinical Oncology</i> , 2006 , 24, 25-35	2.2	958
33	Successful repetitive treatments by electrochemotherapy of multiple unresectable Kaposi sarcoma nodules. <i>European Journal of Cancer, Supplement</i> , 2006 , 4, 29-31	1.6	11
32	Electrochemotherapy [An easy, highly effective and safe treatment of cutaneous and subcutaneous metastases: Results of ESOPE (European Standard Operating Procedures of Electrochemotherapy) study. <i>European Journal of Cancer, Supplement</i> , 2006 , 4, 3-13	1.6	569
31	Impact of surgery on advanced gastrointestinal stromal tumors (GIST) in the imatinib era. <i>Annals of Surgical Oncology</i> , 2006 , 13, 1596-603	3.1	124
30	CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. <i>Journal of Experimental Medicine</i> , 2005 , 202, 1075-85	16.6	687
29	Cutaneous side-effects of kinase inhibitors and blocking antibodies. <i>Lancet Oncology, The</i> , 2005 , 6, 491-500	10.7	429
28	Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of the first phase I clinical trial. <i>Journal of Translational Medicine</i> , 2005 , 3, 10	8.5	769
27	Subungual splinter hemorrhages: a clinical window to inhibition of vascular endothelial growth factor receptors?. <i>Annals of Internal Medicine</i> , 2005 , 143, 313-4	8	50
26	Limb salvage with isolated perfusion for soft tissue sarcoma: could less TNF-alpha be better?. <i>Annals of Oncology</i> , 2005 , 16, 1061-8	10.3	97
25	Selective accumulation of mature DC-Lamp+ dendritic cells in tumor sites is associated with efficient T-cell-mediated antitumor response and control of metastatic dissemination in melanoma. <i>Cancer Research</i> , 2004 , 64, 2192-8	10.1	85
24	Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects. <i>Journal of Clinical Investigation</i> , 2004 , 114, 379-88	15.9	218

23	Doppler-Ultrasonography with perfusion software and contrast medium injection as an early evaluation tool of gastro intestinal stromal tumor (GIST) treated by imatinib: Results of a prospective study. <i>Journal of Clinical Oncology</i> , 2004 , 22, 9048-9048	2.2	2
22	Gene therapy to target dendritic cells from blood to lymph nodes. <i>Gene Therapy</i> , 2003 , 10, 1479-86	4	22
21	Tyrosine kinase inhibition and grey hair. <i>Lancet, The</i> , 2003 , 361, 1056	40	36
20	Homing receptors: potential therapeutical tools?. <i>Experimental Dermatology</i> , 2002 , 11, 472-473	4	
19	Immature mouse dendritic cells enter inflamed tissue, a process that requires E- and P-selectin, but not P-selectin glycoprotein ligand 1. <i>Blood</i> , 2002 , 99, 946-56	2.2	72
18	Immature mouse dendritic cells enter inflamed tissue, a process that requires E- and P-selectin, but not P-selectin glycoprotein ligand 1. <i>Blood</i> , 2002 , 99, 946-956	2.2	10
17	MHC class I-related neonatal Fc receptor for IgG is functionally expressed in monocytes, intestinal macrophages, and dendritic cells. <i>Journal of Immunology</i> , 2001 , 166, 3266-76	5.3	247
16	Neutrophils, monocytes, and dendritic cells express the same specialized form of PSGL-1 as do skin-homing memory T cells: cutaneous lymphocyte antigen. <i>Biochemical and Biophysical Research Communications</i> , 2001 , 285, 577-87	3.4	45
15	Interleukin-1 and cutaneous inflammation: a crucial link between innate and acquired immunity. <i>Journal of Investigative Dermatology</i> , 2000 , 114, 602-8	4.3	144
14	Interaction of dendritic cells with skin endothelium: A new perspective on immunosurveillance. <i>Journal of Experimental Medicine</i> , 1999 , 189, 627-36	16.6	158
13	Inflammatory skin diseases, T cells, and immune surveillance. <i>New England Journal of Medicine</i> , 1999 , 341, 1817-28	59.2	388
12	A prospective coagulation study including resistance to activated protein C and mutations in factors V and II in venous leg ulcers. <i>British Journal of Dermatology</i> , 1999 , 141, 259-63	4	15
11	Hypopigmented mycosis fungoides in a light-skinned woman. <i>British Journal of Dermatology</i> , 1998 , 139, 341-3	4	11
10	Malignant hypercalcemia induced by a parathyroid hormone-related protein secreted by a cutaneous squamous cell carcinoma. <i>Archives of Dermatology</i> , 1997 , 133, 113		6
9	Deleterious effects of ultraviolet A radiation in human cells. <i>Mutation Research DNA Repair</i> , 1997 , 383, 1-8		43
8	Malignant melanoma and granulomatosis. <i>British Journal of Dermatology</i> , 1997 , 137, 787-792	4	20
7	Epstein-Barr virus-associated lymphoproliferative disease during methotrexate therapy for psoriasis. <i>Archives of Dermatology</i> , 1997 , 133, 867-871		42
6	HIV-negative patient with HHV-8 DNA follicular B-cell lymphoma associated with Kaposi's sarcoma. <i>Lancet, The</i> , 1996 , 347, 1042-3	40	10

5	Cell survival and shuttle vector mutagenesis induced by ultraviolet A and ultraviolet B radiation in a human cell line. <i>Journal of Investigative Dermatology</i> , 1996 , 106, 721-8	4.3	86
4	Hypopigmented mycosis fungoides. <i>Archives of Dermatology</i> , 1994 , 130, 476-480		49
3	Bullous Amyloidosis. <i>Medicine (United States)</i> , 1993 , 72, 38-44	1.8	28
2	A case of Rothmund-Thomson syndrome with reduced DNA repair capacity. <i>Archives of Dermatology</i> , 1993 , 129, 332-336		30
1	Nail Abnormalities in Oncology Practice 115-121		1